Author: Nzalapan, Samuel ; Dahl, Ellen ; Cabrol, Jean-Clément ; Righetti, Anna ; Rambaud, Clotilde ; Lechevalier, Pauline ; Duc, Geraldine ; Chèvre, Corinne ; Wanteu, Theo ; Sarafini, Micaela ; Bottineau, Marie-Claude ; Rull, Monica ; Albela, Manuel ; Nesbitt, Robin ; Reache, Souheil ; Peyraud, Nicolas ; Gignoux, Etienne ; Dumont, Thierry ; Quéré, Michel

OBJECTIVETo rapidly increase childhood immunization through a preventive, multi-antigen, vaccination campaign in Mambéré-Kadéï prefecture, Central African Republic, where a conflict from 2012 to 2015 reduced vaccination coverage.METHODSThe three-round campaign took place between December 2015 and June 2016 using: (i) oral poliomyelitis vaccine (OPV); (ii) combined diphtheria, tetanus and pertussis (DTP) vaccine, Haemophilus influenza type B (Hib) and hepatitis B (DTP-Hib-hepatitis B) vaccine; (iii) pneumococcal conjugate vaccine (PCV); (iv) measles vaccine; and (v) yellow fever vaccine. Administrative data were collected on vaccines administered by age group and vaccination coverage surveys were carried out before and after the campaign.FINDINGSOverall, 294 054 vaccine doses were administered. Vaccination coverage for children aged 6 weeks to 59 months increased to over 85% for the first doses of OPV, DTP-Hib-hepatitis B vaccine and PCV and, in children aged 9 weeks to 59 months, to over 70% for the first measles vaccine dose. In children aged 6 weeks to 23 months, coverage of the second doses of OPV, DTP-Hib-hepatitis B vaccine and PCV was over 58% and coverage of the third doses of OPV and DTP-Hib-hepatitis B vaccine was over 20%. Moreover, 61% (5804/9589) of children aged 12 to 23 months had received two PCV doses and 90% (25933/28764) aged 24 to 59 months had received one dose.CONCLUSIONA preventive, multi-antigen, vaccination campaign was effective in rapidly increasing immunization coverage in a post-conflict setting. To sustain high coverage, routine immunization must be reinforced.

19 May 2017·Immunological InvestigationsQ3 · MEDICINE

Influence of the Co-Administration of Heptavalent Conjugate Vaccine PCV7-TT on the Immunological Response Elicited by VA-MENGOC-BC® and Heberpenta®-L in Rabbits

Q3 · MEDICINE

Article

Author: Nicot, Milagros ; Martin, Yanet ; Valdés, Yury ; Valle, Orialys ; Núñez, Juan F ; Espinosa-Viñals, Carlos ; Vérez Bencomo, Vicente ; Santana, Darielys ; García-Rivera, Dagmar ; Amador Gómez, Aylín ; Rodríguez Noda, Laura

Finlay Vaccine Institute is developing a new heptavalent conjugate vaccine against Streptococcus pneumoniae. As infants are the target population, PCV7-TT will be necessarily co-administered with other vaccines, and then, the interactions represent a concern. The aim of this work is to evaluate the possible immunological interferences in rabbits as animal experimental model. Rabbits were immunized with Heberpenta®-L, VA-MENGOC-BC®, and PCV7-TT. Blood samples were taken fourteen days after final immunization for obtaining sera. Antibody responses to all antigens were evaluated by indirect ELISA. Functional responses against diphtheria and tetanus toxoid were done by in vivo seroneutralization assay. No interference was observed by PCV7-TT over the humoral response against diphtheria toxoid and meningococcal antigens (p > 0.05). A nonstatistically significant reduction (p > 0.05) was observed in the case of the humoral response against Haemophilus influenzae type b oligosaccharide. Concomitant administration of Heberpenta®-L and PCV7-TT increased twice the antibody titers as well as the protective activity against tetanus toxoid, but no statistical differences were found. The co-administration did not induce a reduction in the percent of responders against pneumococcal polysaccharides contained in PCV7-TT vaccine. Concomitant administration of PCV7-TT did not induce interferences over the evaluated antigens of Heberpenta®-L and VA-MENGOC-BC®. Also, no interference was observed on the immune response elicited by PCV7-TT. These preclinical results suggest that PCV7-TT will not result in a serious problem over the immune response elicited by the licensed vaccines Heberpenta®-L and VA-MENGOC-BC®. However, the clinical interference could be strictly studied during clinical trials in infants.

01 Sep 1967·Acta pharmaceutica Suecica

Acetylene compounds of potential pharmacological value. IX. N-(4-dialkylamino-2-butynyl)-substituted carboxylic and sulphonic acid amides.

Article

Author: Lindquist, A ; Dahlbom, R ; Karlén, B ; Jenden, D J ; George, R

100 Deals associated with Hib-DTP-hepatitis B vaccine(Center For Genetic Engineering And Biotechnology)

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	J07CA11	-

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Diphtheria	CU	Centro de Ingenieria Genetica y Biotecnologia	31 Jul 2016
Haemophilus Infections	CU	Centro de Ingenieria Genetica y Biotecnologia	31 Jul 2016
Hepatitis B	CU	Centro de Ingenieria Genetica y Biotecnologia	31 Jul 2016
Tetanus	CU	Centro de Ingenieria Genetica y Biotecnologia	31 Jul 2016
Whooping Cough	CU	Centro de Ingenieria Genetica y Biotecnologia	31 Jul 2016

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

Hib-DTP-hepatitis B vaccine(Center For Genetic Engineering And Biotechnology)

Overview

Basic Info

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation